• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Gentian Diagnostics

Less than 1K followers

GENT

Oslo Børs

Medical Equipment & Services

Health Care

Overview
Investor consensus

Gentian Diagnostics is a medical diagnostics company that develops and manufactures in vitro diagnostic reagents for high-throughput analyzers. Gentian's expertise and focus lies in homogeneous immunoassays, specifically infections, inflammation, renal failure and congestive heart failure. The company's headquarters and production facilities are located in Moss, Norway, and serves the global human and veterinary diagnostics market through sales and representative offices in a number of key countries.

Read more
Market cap
-
Turnover
-
Revenue
176.5M
EBIT %
14.42 %
P/E
-
Dividend yield-%
-
Financial calendar
20.10
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Regulatory press release09.07.2026, 07.30

Gentian Diagnostics - Second quarter 2026 report

Gentian Diagnostics
Regulatory press release02.07.2026, 13.18

Gentian Diagnostics: Invitation to presentation of second quarter results

Gentian Diagnostics
Regulatory press release24.06.2026, 08.30

GENT: ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT

Gentian Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release29.05.2026, 13.32

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release13.05.2026, 08.00

GENT: Meldepliktig handel og endring i styret

Gentian Diagnostics
Regulatory press release13.05.2026, 08.00

Flaggemelding - Gentian Diagnostics ASA

Gentian Diagnostics
Regulatory press release13.05.2026, 08.00

GENT: Board resignation

Gentian Diagnostics
Regulatory press release06.05.2026, 07.30

Gentian Diagnostics: First quarter 2026 report

Gentian Diagnostics
Regulatory press release06.05.2026, 07.30

GENT: Gentian Diagnostics ASA terminates NT-proBNP assay development

Gentian Diagnostics
Regulatory press release06.05.2026, 06.50

Gentian Diagnostics: Ex dividend NOK 0.60 today

Gentian Diagnostics
Regulatory press release05.05.2026, 11.57

Gentian Diagnostics: Minutes from Annual General Meeting

Gentian Diagnostics
Regulatory press release29.04.2026, 14.04

Gentian Diagnostics: Invitation to presentation of first quarter results

Gentian Diagnostics
Regulatory press release20.04.2026, 11.04

GENT: Gentian Diagnostics renews long-term faecal calprotectin partnership with Bühlmann Laboratories

Gentian Diagnostics
Regulatory press release13.04.2026, 13.20

Gentian Diagnostics: Notice of annual general meeting

Gentian Diagnostics
Regulatory press release10.04.2026, 10.02

Gentian Diagnostics ASA - Registration of share capital increase

Gentian Diagnostics
Regulatory press release20.03.2026, 08.36

Gentian Diagnostics: Annual report 2025

Gentian Diagnostics
Regulatory press release12.03.2026, 10.36

Gentian Diagnostics ASA - Mandatory notification of subscription of shares by primary insiders in Employee Share Purchase Program

Gentian Diagnostics
Regulatory press release12.03.2026, 10.36

Gentian Diagnostics ASA - Employee Share Purchase Program and share capital increase

Gentian Diagnostics
Regulatory press release19.02.2026, 10.21

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release13.02.2026, 09.26

GENT: Mandatory notification of trade

Gentian Diagnostics